Cargando…
A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both β-Catenin and RAS
Treatment of advanced gastric cancer patients with current standard chemotherapeutic agents frequently results in resistance, leading to poor overall survival. However, there has been no success in developing strategies to overcome it. We showed the expression levels of both β-catenin and RAS were s...
Autores principales: | Ryu, Won-Ji, Lee, Jae Eun, Cho, Yong-Hee, Lee, Gunho, Seo, Mi-kyoung, Lee, Sang-Kyu, Hwang, Jeong-Ha, Min, Do Sik, Noh, Sung Hoon, Paik, Soonmyung, Kim, Sangwoo, Cheong, Jae-Ho, Choi, Kang-Yell |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521309/ https://www.ncbi.nlm.nih.gov/pubmed/30965636 http://dx.doi.org/10.3390/cancers11040496 |
Ejemplares similares
-
Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer
por: Ryu, Won-Ji, et al.
Publicado: (2020) -
Small molecule-induced simultaneous destabilization of β-catenin and RAS is an effective molecular strategy to suppress stemness of colorectal cancer cells
por: Cho, Yong-Hee, et al.
Publicado: (2020) -
Simultaneous destabilization of β-catenin and Ras via targeting of the axin-RGS domain as a potential therapeutic strategy for colorectal cancer
por: Cha, Pu-Hyeon, et al.
Publicado: (2016) -
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer
por: Park, Jieun, et al.
Publicado: (2019) -
An Improved, Assay Platform Agnostic, Absolute Single Sample Breast Cancer Subtype Classifier
por: Seo, Mi-kyoung, et al.
Publicado: (2020)